Ironwood Investment Management LLC Selecta Biosciences Inc Transaction History

Ironwood Investment Management LLC

$179 Million
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.62 - $0.85 $3,837 - $5,261	6,190 Added 3.63%	176,816 $148,000
Q4 2023 Feb 14, 2024	SELL	$0.67 - $1.35 $5,698 - $11,481	-8,505 Reduced 4.75%	170,626 $117,000
Q3 2023 Nov 16, 2023	SELL	$1.02 - $1.23 $6,158 - $7,426	-6,038 Reduced 3.26%	179,131 $189,000
Q2 2023 Aug 11, 2023	SELL	$1.04 - $1.4 $3,840 - $5,170	-3,693 Reduced 1.96%	185,169 $207,000
Q1 2023 May 15, 2023	BUY	$1.15 - $1.89 $13,431 - $22,075	11,680 Added 6.59%	188,862 $262,000
Q4 2022 Jan 31, 2023	SELL	$0.96 - $1.6 $21,076 - $35,128	-21,955 Reduced 11.03%	177,182 $200,000
Q3 2022 Nov 14, 2022	BUY	$1.33 - $2.6 $680 - $1,331	512 Added 0.26%	199,137 $327,000
Q2 2022 Aug 12, 2022	BUY	$0.67 - $1.4 $58 - $123	88 Added 0.04%	198,625 $260,000
Q1 2022 May 10, 2022	BUY	$1.23 - $3.31 $7,157 - $19,260	5,819 Added 3.02%	198,537 $244,000
Q4 2021 Feb 10, 2022	BUY	$2.89 - $4.43 $560 - $859	194 Added 0.1%	192,718 $628,000
Q3 2021 Nov 12, 2021	BUY	$3.36 - $4.62 $1,616 - $2,222	481 Added 0.25%	192,524 $801,000
Q2 2021 Aug 16, 2021	SELL	$2.82 - $5.01 $12,723 - $22,605	-4,512 Reduced 2.3%	192,043 $803,000
Q1 2021 May 14, 2021	BUY	$2.92 - $5.07 $5,256 - $9,126	1,800 Added 0.92%	196,555 $889,000
Q4 2020 Feb 12, 2021	SELL	$1.64 - $3.42 $8,800 - $18,351	-5,366 Reduced 2.68%	194,755 $590,000
Q3 2020 Nov 13, 2020	SELL	$2.18 - $2.84 $1,018 - $1,326	-467 Reduced 0.23%	200,121 $496,000
Q2 2020 Aug 17, 2020	BUY	$1.83 - $4.06 $215,369 - $477,813	117,688 Added 141.96%	200,588 $570,000
Q1 2020 May 14, 2020	BUY	$1.5 - $4.52 $124,350 - $374,707	82,900 New	82,900 $200,000

Others Institutions Holding SELB

# of Institutions

Shares Held

4.67M

Call Options Held

Put Options Held

View Full List

About SELECTA BIOSCIENCES INC

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

More about SELB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ironwood Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ironwood Investment Management LLC with notifications on news.

Account